eXoZymes (NASDAQ:EXOZ) Releases Quarterly Earnings Results

eXoZymes (NASDAQ:EXOZ) announced its quarterly earnings data on Thursday. The company reported ($0.33) EPS for the quarter, Zacks reports.

eXoZymes Trading Down 3.0%

Shares of eXoZymes stock traded down $0.18 during trading on Friday, hitting $5.82. The stock had a trading volume of 9,086 shares, compared to its average volume of 6,777. The stock has a 50 day simple moving average of $6.53 and a 200 day simple moving average of $8.40. The company has a market capitalization of $53.60 million, a PE ratio of -4.89 and a beta of 2.93. The company has a quick ratio of 1.32, a current ratio of 1.32 and a debt-to-equity ratio of 0.03. eXoZymes has a 1 year low of $4.35 and a 1 year high of $18.40.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of eXoZymes in a report on Friday, May 29th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has an average rating of “Sell”.

About eXoZymes

eXoZymes, Inc develops, manufactures and supplies a range of enzymes and reagents designed for molecular biology research and diagnostic applications. The company’s enzyme engineering platform underpins a portfolio of products aimed at supporting nucleic acid purification, amplification and analysis workflows.

Key offerings from eXoZymes include magnetic bead–based nucleic acid extraction kits, DNA polymerases, reverse transcriptases, proteases and custom enzyme services. In addition, the company provides molecular diagnostic test kits designed for pathogen detection, leveraging scalable production processes and quality systems aligned with regulatory standards.

eXoZymes serves academic research institutions, biotechnology and pharmaceutical companies, and clinical diagnostic laboratories worldwide.